MIFS: An adaptive multipath information fused self-supervised framework for drug discovery.

Neural Netw

Chongqing Key Laboratory of Computational Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, China; College of Computer and Information Science, Chongqing Normal University, Chongqing, 401331, China. Electronic address:

Published: January 2025

The production of expressive molecular representations with scarce labeled data is challenging for AI-driven drug discovery. Mainstream studies often follow a pipeline that pre-trains a specific molecular encoder and then fine-tunes it. However, the significant challenges of these methods are (1) neglecting the propagation of diverse information within molecules and (2) the absence of knowledge and chemical constraints in the pre-training strategy. In this study, we propose an adaptive multipath information fused self-supervised framework (MIFS) that explores molecular representations from large-scale unlabeled data to aid drug discovery. In MIFS, we innovatively design a dedicated molecular graph encoder called Mol-EN, which implements three pathways of information propagation: atom-to-atom, chemical bond-to-atom, and group-to-atom, to comprehensively perceive and capture abundant semantic information. Furthermore, a novel adaptive pre-training strategy based on molecular scaffolds is devised to pre-train Mol-EN on 11 million unlabeled molecules. It optimizes Mol-EN by constructing a topological contrastive loss to provide additional chemical insights into molecular structures. Subsequently, the pre-trained Mol-EN is fine-tuned on 14 widespread drug discovery benchmark datasets, including molecular properties prediction, drug-target interactions, and drug-drug interactions. Notably, to further enhance chemical knowledge, we introduce an elemental knowledge graph (ElementKG) in the fine-tuning phase. Extensive experiments show that MIFS achieves competitive performance while providing plausible explanations for predictions from a chemical perspective.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neunet.2024.107088DOI Listing

Publication Analysis

Top Keywords

drug discovery
16
adaptive multipath
8
multipath fused
8
fused self-supervised
8
self-supervised framework
8
molecular representations
8
pre-training strategy
8
molecular
7
chemical
5
mifs
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Sage Bionetworks, Seattle, WA, USA.

Background: There is an urgent need for new therapeutic and diagnostic targets for Alzheimer's disease (AD). Dementia afflicts roughly 55 million individuals worldwide, and the prevalence is increasing with longer lifespans and the absence of preventive therapies. Given the demonstrated heterogeneity of Alzheimer's disease in biological and genetic components, it is critical to identify new therapeutic approaches.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: The ability to monitor cognitive trajectories over the course of trials can provide valuable insights into treatment efficacy. However, existing trial methods are limited in monitoring cognition in real-time and at high frequencies. Gameplay-based assessments hold promise as complementary cognitive tools.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Yonsei University, Incheon, Incheon, Korea, Republic of (South).

Background: Cyclin Y (CCNY) is a member of cyclin protein family inhibiting long-term synaptic plasticity, which is related to the learning and memory function in neuronal system. Recently, CCNY has been reported to associate with the cognitive deficits in Alzheimer's disease (AD).

Method: In this study, we discovered PFTAIRE peptide to diminish CCNY protein level and to ameliorate cognitive dysfunction in AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Yonsei University, Incheon, Incheon, Korea, Republic of (South).

Background: As amyloid-β (Aβ) aggregates are considered as the biomarkers and key factors in the pathology of Alzheimer's disease, there has been extensive investigation into Aβ-targeting compounds for the development of diagnostics and drug discovery related to the disorder. However, the polymorphic and heterogenous nature of Aβ aggregates impedes the structural understanding of their structure. Consequently it is a major challenge to develop new diagnostic and therapeutic development of AD and to study the mechanism of Aβ-targeting compounds.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Background: Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder with limited treatment options. As it progresses, synapse degeneration is the most important feature contributing to cognitive dysfunction. Mitochondria supply synapses with ATP for neurotransmitter release and vesicle recycling and buffer calcium concentrations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!